Identification of Circulating Tumor Cells in Patients with HPV 16 or 18 Associated Cervical Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Cervical Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1) Able to safely provide 15 ml of blood 2) Pathologically confirmed invasive cervical cancer 3) Proof of serotype HPV 16 or HPV 18 positive within 3 years of the study 4) Patients with stages IIA2 to IVB OR recurrent cervical cancer 5) For patients with newly diagnosed cervical cancer, they must be enrolled (blood drawn) prior to initiating anti-cancer therapy 6) For patients with recurrent cervical cancer, they must be enrolled (blood drawn) prior to initiating a new anti-cancer therapy for progression of disease (based on RECIST 1.1 criteria). Patients who have progressed and are moving to best supportive care are eligible.

You may not be eligible for this study if the following are true:

  • 1) History of any cancer other than cervix cancer within the past five years. 2) History of any known germ-line pathogenic mutation (ie BRCA 1 / 2 or Lynch syndrome, but genetic testing is not required) 3) Current use of systemic corticosteroids at doses exceeding 10 mg per day of prednisone or its equivalent. 4) Active infection including hepatitis B, hepatitis C, HIV. 5) Any patient unable to comply with the study criteria. 6) Patients taking any anti-inflammatory agents (aspirin, NSAIDs, steroids), within 24 hrs prior to blood draw.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.